A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

NCT05621434 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

63

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Recurrent/Metastatic Breast Cancer

Interventions

DRUG: Inetetamab, pyrotinib, chemotherapy

Sponsor

Fujian Medical University